Time Restricted Eating in Haematological Malignancies

Launched by BRITISH COLUMBIA CANCER AGENCY · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Time Restricted Eating in Haematological Malignancies," is exploring whether a specific eating pattern called time-restricted eating (TRE) can help improve health for patients with chronic lymphocytic leukemia (CLL), a type of cancer. TRE involves eating normally for 8 hours each day and fasting for the remaining 16 hours. The trial aims to see if this eating pattern can lower cancer cell counts, affect immune cell recycling (a process that keeps cells healthy), and enhance the overall quality of life for participants.

To be eligible for this study, participants must be between 18 to 85 years old and have a diagnosis of CLL or a similar condition. They should not have followed any form of intermittent fasting for the four months before joining the study. Participants will be asked to follow the TRE regimen for either 3 or 6 months, keep track of their meals and weight, and attend regular check-ins with the study team. They will also provide blood samples and complete questionnaires about their quality of life. This study is currently not recruiting participants, but it is important for those interested to know that they will need to meet specific health criteria to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Experimental Participants:
• • Diagnosis of CLL or SLL, Age 18-85
• • Peripheral blood lymphocytes \>20 x 10\^9/L
• • Hemoglobin \>90g/L
• • Platelets ˃90 x 10\^9/L
• • BMI of \>=20kg/m2
• • ECOG Performance Status \>=2
• • Not following any form of IF for 4 months prior to study
• Control Participants:
• • Absence of cancer diagnosis (active or historical)
• • Age 18-85, Peripheral blood lymphocytes \<5 x10\^9/L
• • BMI of \>=20kg/m2
• • ECOG Performance Status \>=2
• • Not following any form of IF for 4 months prior to study
• Exclusion Criteria:
• Experimental and Control Participants:
• • Unable to give consent
• • On medications required to be taken with food during the fasting window
• • Pregnant or breastfeeding
• • Diabetes mellitus
• • BMI drop to \< 18.5kg/m2 at any time during study
• • Anti-lymphoma therapy within the past 3 months
• • Expected to initiate anti-lymphoma therapy within the next 3 months
• • Unable to fast due to a digestive system disorder
• • \> 85 years of age (due to frailty, increased risk of infection, and burden of additional blood collections)